Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tideglusib for the Treatment of Amyotrophic Lateral Sclerosis (TIDALS): a Randomized Placebo-controlled Phase II Trial

NCT05105958 is registered in ClinicalTrials.gov with University of Zurich as lead sponsor.

NCT NCT05105958
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05105958 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tideglusib for the Treatment of Amyotrophic Lateral Sclerosis (TIDALS): a Randomized Placebo-controlled Phase II Trial
Lead sponsor
University of Zurich
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 1, 2025
Completion date
March 1, 2026
Enrollment
98 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis